Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Precigen heads into its November earnings with shorts gradually unwinding, retail attention spiking, and a freshly initiated analyst coverage expanding the bull case, even as the stock slips 6% on the week.
Short interest remains elevated but is clearly declining. Bears hold 11.3% of the free float short, down from roughly 11.8% a month ago and continuing a steady bleed since mid-September, when the position was closer to 12%. The borrow market is not flashing any squeeze risk. Availability is generous at 154%, meaning there are roughly 1.5 shares available to lend for every one already borrowed, well off the 52-week tightest reading of 13.7%. Cost to borrow has also eased, running below 0.45%, down 12% over the past month. Bears can add here cheaply and without friction, which makes the ongoing decline in short interest a choice rather than a forced cover. The ORTEX short score remains elevated at 73.7, consistent with a name that carries meaningful bearish conviction but where that conviction is very slowly fading.
Options positioning reinforces the impression of a market leaning bullish on the stock rather than hedging against it. The put/call ratio is extremely low at 0.075, barely above the 20-day average of 0.070 and a universe away from the 52-week high of 1.18. Calls dominate by a wide margin. That is not defensive hedging, it is a market where participants are buying upside, not buying protection.
Coverage from the Street is uniformly positive, though small. B. Riley Securities initiated with a Buy and a $12 target in late September, joining HC Wainwright, which raised its target to $18 following August's earnings. Both firms are bullish, and no analyst in the current coverage universe holds anything below a Buy. The consensus target of $13.65 implies roughly 81% upside from the current $7.55 close, a wide gap that reflects either genuine conviction in the pipeline or the thin coverage base that typically accompanies small-cap biotechs in commercial ramp mode. The analyst recommendation factor score ranks in the 92nd percentile, one of the highest readings in the universe.
The bull case rests on PAPZIMEOS, the only FDA-approved therapy for adult recurrent respiratory papillomatosis, which carries orphan-drug exclusivity through 2032. Second full-quarter sales of $53.1 million outpaced comparable rare-oncology launches, and 15 of 18 complete responses remained ongoing beyond 36 months. HC Wainwright models US revenue reaching $1.5 billion by 2035. On September 21, the AdenoVerse platform received an FDA Platform Technology Designation, adding a potential pipeline catalyst to the commercial story. The bear case is more structural: revenue recognition is lumpy, the $460,000 four-dose regimen spans two calendar quarters, and every asset beyond PAPZIMEOS remains unapproved and dependent on FDA outcomes that are not guaranteed.
The ownership structure deserves attention. Randal Kirk filed a Schedule 13D, making him a registered activist holder, with a stake that last disclosed stood at 35.9% of shares, reduced from 38.1% at the prior filing. That is an unusual concentration of activist interest in a name of this size. Third Security, the institutional vehicle associated with Kirk, accounts for a further 29% of shares. Alongside that, retail attention has climbed sharply: Wikipedia views carry a z-score of 2.2 against the stock's own 90-day history, the highest signal in the alt data layer, suggesting the PAPZIMEOS commercial story is attracting meaningful public interest beyond the traditional biotech investor base. BlackRock added 1.9 million shares through September 30, and State Street added 1.1 million across the same period.
The next earnings print is scheduled for November 4. Given that the August report produced a 5% one-day decline followed by a recovery to a modest 4% gain over five days, and the most recent quarter produced a straight 4% move in both directions, the setup into that date is where to focus next: whether short interest continues its gradual retreat or stabilises, and whether the wide gap between the current price and analyst targets begins to close on any positive data from the pipeline.
See the live data behind this article on ORTEX.
Open PGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
